News

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12,…

7 months ago

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12,…

7 months ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

SteraMist Named Disinfection and Decontamination Products Company of the Year 2025

FREDERICK, Md., June 12, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

7 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

7 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

7 months ago